Onchilles plans to initiate a first-in-human trial of N17350, a tumor-directed injectable, in patients in Australia early next year, with IND clearance in the United States and U.S. patient enrollment expected in mid-2026. The study will evaluate safety, monotherapy activity, and biomarkers of immune activation across multiple solid tumor types, including breast, skin, and head and neck cancers.

First-in-class therapeutic, N17350, demonstrates potent and selective tumor killing in chemotherapy-naïve and chemotherapy-treated ovarian cancer patient-derived models